Vaccinia virus vTF7-3

Classification: Poxviridae, Orthopoxvirus

Classification   Poxviridae, Orthopoxvirus

Agent       Vacciniavirus

Strain        vTF7-3[Wr]

Applications     Expresses bacteriophage T[7] RNA polymerase.

Expresses bacteriophage T[7] RNApolymerase.

Biosafety Level         2

Isolation  Constructedin vitro

Product Format        frozen

Storage Conditions  -70°C

Comments       Cellswhich have been infected with this construct can be transfected by plasmidswhich contain a gene targeted for expression inserted between a T7 promoter andT7 terminator.

Expresses bacteriophage T[7] RNApolymerase.

Recombinant virus constructed in vitro.

Expresses bacteriophage T[7] RNA polymerase.

Expression of the T7 RNA polymerase isdirected by the P7.5 promoter which includes early and late regulatory signals.

Constructed by transfecting vacciniavirus-infected cells with pTF703

Effect on Host Yes, in vitro effects: Cytopathic effects (plaque formation) onBS-C-1 and CV-1 monolayers

CPE, rounding, stringing, and celldestruction

Effect on Host Yes, in vitro effects: Cytopathic effects (plaque formation) onBS-C-1 and CV-1 monolayers

CPE, rounding, stringing, and celldestruction

Name of Depositor  NIH, B Moss, NIH

U.S. Patent       5,550,035

U.S. Patent Number         5,550,035

Source      Constructedin vitro

References       FuerstTR, et al. Eukaryotic transient-expression system based on recombinant vacciniavirus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci.USA 83: 8122-8126, 1986. PubMed: 3095828